All In Biotech

Drug Trial Radar · NCT03024255

A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis

Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 227 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

227

Actual

Start

Dec 22, 2016

Primary completion

Sep 19, 2017

Study completion Sep 19, 2017

Sponsor

Lead sponsor
Botanix PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to assess the safety and efficacy of 3 concentrations of BBI-4000 and vehicle (4 treatment arms), applied for the treatment of axillary hyperhidrosis.

Conditions

  • Hyperhidrosis

Interventions

  • BBI-4000 gel, 5%Drug

    BBI-4000 gel, 5% applied once to each axilla daily

  • BBI-4000 gel, 10%Drug

    BBI-4000 gel, 10% applied once to each axilla daily

  • BBI-4000 gel, 15%Drug

    BBI-4000 gel, 15% applied once to each axilla daily

  • Vehicle (Placebo)Drug

    Placebo, applied once to each axilla daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of TherapyTime frame: overall ~6 Weeks, as listed in description includes: Baseline-Visit 1, Visit 4 and End of Therapy Visit - Days 41, 42, 43.
  2. Number (%) of Subjects Reporting at Least One Treatment Emergent Adverse Event by SeverityTime frame: Treatment initiation through end of treatment (~42 days) and subsequent safety f/u (~14 days following end of treatment)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.